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Abstract
Background: Over the past decades there has been a significant increase in the number of published clinical trials
in palliative care. However, empirical evidence suggests that there are methodological problems in the design and
conduct of studies, which raises questions about the validity and generalisability of the results and of the strength of
the available evidence. We sought to evaluate the methodological characteristics and assess the quality of reporting of
clinical trials in palliative care.
Methods: We performed a systematic review of published clinical trials assessing therapeutic interventions in
palliative care. Trials were identified using MEDLINE (from its inception to February 2015). We assessed methodological
characteristics and describe the quality of reporting using the Cochrane Risk of Bias tool.
Results: We retrieved 107 studies. The most common medical field studied was oncology, and 43.9% of trials evaluated
pharmacological interventions. Symptom control and physical dimensions (e.g. intervention on pain, breathlessness,
nausea) were the palliative care-specific issues most studied. We found under-reporting of key information in particular on
random sequence generation, allocation concealment, and blinding.
Conclusions: While the number of clinical trials in palliative care has increased over time, methodological quality remains
suboptimal. This compromises the quality of studies. Therefore, a greater effort is needed to enable the appropriate
performance of future studies and increase the robustness of evidence-based medicine in this important field.
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Background
From the first time it was used, the concept of “palliative
care” (PC) has suffered a series of transformations in how
it is defined and consequently in the relevant area of oper-
ation and objectives [1, 2]. In 2002 the World Health
Organization affirmed that PC improves the quality of life
of patients and their families facing problems associated
with life-threatening illness, through the prevention and
relief of suffering by means of early identification and im-
peccable assessment and treatment of pain and other
physical, psychosocial, and spiritual issues [1, 3].
Changes in demographic trends, including the ageing
of populations and the increased life expectancy of
individuals with life-limiting illnesses, have increased
demand for high quality PC services. Today, the initi-
ation of a treatment on the basis on what is believed to
be effective is no longer considered good clinical prac-
tice [4]. A clinician in addition to his clinical expertise,
must have access to the best available evidence, should
carefully appraise its quality and assess its applicability
to each individual patient [5, 6].
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According to a MEDLINE search, the number of PC
clinical trials (CT) published has quadrupled, from incep-
tion to 2005 [7, 8]. Whilst this may be beneficial, questions
exist around the type and quality of the research being
undertaken. Previous reviews have concluded that PC
studies were largely descriptive, with a wide variation in
sample size, in demographic and clinical aspects and with
a lack of use of recognised standard measures and consid-
eration of key outcomes [5, 6, 9–12]. Visser et al. [5] stud-
ied the reality of evidence-based practice in palliative care
and highlighted additional problems like unpowered stud-
ies, recruitment difficulties and high attrition rates, inad-
equate duration of follow-up and difficulty in defining
outcomes and avoiding performance bias [5, 9, 13].
In response to the high variability of clinical practice
and the increasing costs and complexity of care, evidence
is needed to define what are the most effective treatments.
Good quality randomized controlled trials (RCTs) are the
gold standard for evaluating the efficacy and effectiveness
of health care interventions [14, 15]. Since previous publi-
cations showed a low number of randomized clinical trials
(RCT) in the palliative care field, to achieve a more com-
prehensive view of therapeutic palliative care research, we
designed a broad search strategy including all types of
controlled clinical trials (CCT), of which RCT represent a
subgroup [14, 15]. The goal of this systematic review was
to evaluate the methodological characteristics of CCT in
palliative care and to assess their quality of reporting.
Methods
Literature search
We performed a MEDLINE search through Ovid from in-
ception (1946) to February 2015 using a pre-defined search
strategy (Additional file 1) designed by the authors based
on The Cochrane Collaboration’s highly sensitive search
strategy to identify RCTs in the field of palliative care.
Study selection
Inclusion criteria for studies were:
 prospective controlled clinical study;
 pharmacological and non-pharmacological
interventions;
 studies evaluating palliative care interventions
(according to each of the authors’ definition)
conducted in patients and/or family members or
caregivers, regardless the place of care;
 full-length article available.
We excluded:
 non-experimental studies (observational studies,
systematic reviews, methodological studies, study
protocols);
 experimental studies which did not evaluate
palliative care interventions;
 experimental studies evaluating palliative care
interventions not directly focused in patient-family
dyad (cost-effectiveness analysis, evaluation of pallia-
tive care services/units, and interventions directed at
health professionals).
Titles and abstracts of citations were independently
pre-screened by two reviewers (RB, MR) according to re-
view study selection criteria. The inclusion or exclusion
criteria were applied and studies were selected for con-
sideration on the basis of full text reports. Two re-
viewers independently assessed the full study reports;
disagreements were resolved by consensus or by consult-
ation with a third reviewer (JJF).
Data extraction and quality assessment
Before study selection, a data extraction form with 43
items was developed, based on the checklist of guidelines
for the design and evaluation of clinical trials (CONSORT,
SPIRIT) [16–18]. Data extraction was done manually by
two researchers (RBM, MR) without any extraction soft-
ware. Five domains were analysed:
 general information (title of the CCT, name and
country of the corresponding author, language of
publication, year and journal of publication, journal
impact factor, area and type of intervention, personal
dimension and key points of practice of PC
evaluated, ethical approval and informed consent);
 methods (eligible criteria, type of study design,
method of randomisation, achievement of allocation
concealment, type of blinding, and duration of
follow-up);
 sample (intervention, total number of randomised
patients and number of patients in each group,
duration and timing of treatment, dropout rate, and
sample size calculation);
 data analysis (type of analysis, statistical methods
used, pre-defined outcomes, assessment tools, and
group comparability);
 results.
Included articles were classified by clinical domain (e.g.
oncology, neurology) and type of intervention. Four types
of interventions were considered: pharmacological, non-
pharmacological (all non-pharmacological interventions
provided by health care professionals that are specifically
mentioned as part of the interdisciplinary palliative care
interventions [19]), non-pharmacological complementary
therapies (all non-pharmacological interventions, such as
musical and aromatherapy, that are not considered as part
of the core palliative care interdisciplinary interventions
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[19]), and home-care based (all pharmacological and non-
pharmacological interventions provided in patient’s
home).
We identified PC milestones (focus on whole-person,
patient and family empowerment, good communication,
improvement of quality of life and teamwork) most rele-
vant in the aims of each study. Based on them, we pro-
ceeded with two different types of classifications, one
according to the main personal dimensions (physical,
psychological, social or spiritual dimensions), and a sec-
ond level in line with other factors of PC practice (com-
munication, symptoms control, family support and team
work) [20, 21].
The methodological quality of the included studies was
assessed using the Cochrane Risk of Bias (RoB) tool [22].
This tool quantifies the association between certain design
features and estimates of treatment effects. The RoB tool
is a two-part instrument and includes the following areas:
sequence generation, allocation concealment, blinding (of
participants, investigators and outcome assessment), in-
complete outcome data, selective outcome reporting and
“other issues”. The first part refers to the description of
what was reported in the trial, detailed enough for a
judgement to be made based on this information. The sec-
ond part appraises the risk of bias for each analysed area
and classifies them in three categories: low, high or un-
clear risk of bias [15, 23].
Independently, two authors (RBM, MR) extracted in-
formation on individual items from all included studies
and assessed the two parts in each study. Discrepancies
were resolved through discussion or by consultation
with a third reviewer (JJF).
Statistical analysis
We summarised the publication characteristics using
frequencies and percentages. Pooled odd ratios (OR) and
the 95% confidence interval (CI) were calculated using a
random effects model. This method offers summary esti-
mates by combining the individual results published by
independent researchers. It increases power and pro-
duces more precise summary estimates of the risk of
dropout between interventions and control groups [24].
Differing dropout rates between treatment and control
arms, with fewer patients being followed up in one arm
than the other, increases the risk of attrition bias and the
possibility of false-negative results [22, 25]. For this ana-
lysis we used Review Manager 5.3.0 software [22], Mantel-
Haenzel method to account for the heterogeneity (clinical
and methodological) among studies.
Results
The electronic search identified 939 citations. After
screening abstracts 120 articles were deemed potentially
eligible. The application of inclusion criteria excluded 13
studies. The main reasons for exclusion were: repeated
in the list of references (n = 3), duplicated publications
(n = 8) and non-English language (n = 2) (Fig. 1).
General features
Of the 107 clinical trials included (Additional file 2),
12.2% (n = 13) were published between 1989 and 1999,
45.8% (n = 49) between 2000 and 2009, and 41.1% (n = 44)
between 2010 and 2015 (Fig. 2). Studies were published in
fifty-seven different journals, with the most reported
being: Journal of Pain and Symptom Management
(14.9%, n = 16, impact factor [IF]: 2.47), Palliative
Medicine (13.1%, n = 14, IF: 2.85), Journal of Palliative
Medicine (9.3%, n = 10, IF: 2.06) and Journal of Clinical
Oncology (5.6%, n = 6, IF: 17.9). Most studies were con-
ducted in the United States (USA) (26.2%, n = 28), the
United Kingdom (UK) (21.5%, n = 23), Australia (11.2%,
n = 12), and Canada (6.5%, n = 7). Fifteen percent (n = 16)
of all the studies lacked mention of approval by an ethics
committee.
Types of design
Eighty-two point three percent (n = 88) of all the studies
had a parallel design and 17.7% (n = 19) had a crossover
design.
The most used comparator was non-intervention
(control group participants did not receive any interven-
tion for the duration of the study follow-up)/best sup-
portive care (46.7%, n = 50) followed by placebo (27.1%,
n = 29) and other interventions (25.2%, n = 27). The ana-
lysis of type of intervention and type of comparator
demonstrated that non-intervention/best supportive care
was essentially used in non-pharmacological interven-
tions (80%, n = 40), while other interventions and pla-
cebo were more used in pharmacological interventions
(88.9%, n = 24 and 62.1%, n = 18). Another intervention
was chosen more often than placebo in pharmacological
interventions.
Follow-up duration varied between studies. The most
common periods were 1 month (14%, n = 15), 2 months
and 2 weeks (9.3%, n = 10 each). The shortest follow-up
was 30 min (at the end of an intervention) and
54 months was the longest period reported.
Eligibility
Eligibility criteria varied significantly throughout studies.
In the included studies all patients were at least 18 years
old and no studies indicated the gender or ethnicity of
participants. According to what has been previously re-
ported, oncological disease is often an inclusion criter-
ion. In three studies (2.8%), dementia was also an
inclusion criterion, while it was an exclusion criterion in
29 studies (27.1%). The expected remaining lifespan of
participants varied between “less than a week of life” and
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24 months, with 6 months of life being the most com-
monly considered period. In 66.4% (n = 71) of articles
this data was unknown.
Clinical domains
The three clinical domains more present in the palliative
care included studies were: oncology (56.1%, n = 60),
mental health (15.9%, n = 17) and general practice (9.3%,
n = 10) (Fig. 3).
Types of interventions
Regarding the type of intervention, 44.9% (n = 48) of stud-
ies reviewed were non-pharmacological interventions,
43.9% (n = 47) pharmacological interventions, 7.5% (n = 8)
non-pharmacological complementary therapy interventions,
and 3.7% (n = 4) home-care based interventions (all
pharmacological and non-pharmacological interventions
provided in patient’s home. See Fig. 4).
Palliative care classifications
With respect to the personal dimension studied, 63.6%
(n = 68) analysed the physical dimension, 13.1% (n = 14)
the psychological dimension, 14% (n = 15) the social di-
mension and 9.3% (n = 10) the spiritual dimension. By
classifying the studies according to the other key points
of palliative care practice we found that 70.1% (n = 75)
of the studies were based on symptom control evalu-
ation, teamwork and communication both represented
12.1% (n = 13) of studies, and 5.6% (n = 6) studies
highlighted family support.
Fig. 1 Flow diagram of study selection process
Fig. 2 Number of clinical trials published over time
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Outcomes and assessment tools
As expected due to the broad scope of this review, there
was a significant diversity of evaluated clinical outcomes.
However, in 40.2% of the included trials (n = 43) no pri-
mary outcome was defined. When mentioned, the most
cited primary outcomes were: pain intensity (20.3%, n =
13), improvement in quality of life (12.5%, n = 8), im-
provement in dyspnoea (9.4%, n = 6), and survival rate
(7.8%, n = 5). The most common secondary outcomes
were: improvement in quality of life (29.9%, n = 32), im-
provement in depression and anxiety (19.6%, n = 21), use
of rescue doses or palliative care services (15.9%, n = 17),
or presence of side effects (15%, n = 16). In the absence
of a pre-specified main outcome, we considered all out-
comes as secondary.
For outcome assessment 137 different scales and
questionnaires were used, with only eleven (8%) used
in more than five studies. Twenty (14.6%) of the 137
are recommended by the National Palliative Care Re-
search Center, 5 (3.7%) belong to the group of most
used scales (Fig. 5).
Statistic analysis
Four studies (3.7%) failed to describe statistical planning,
only one (0.9%) used descriptive analysis. In the majority
of studies the analysis per protocol was deduced from
the presence of dropouts and the absence of intention-
to-treat analysis reporting. Half the studies (50.5%, n =
54) used intention-to-treat analysis, 47.7% (n = 51) ana-
lysis per protocol and in two articles (1.9%) it was not
Fig. 3 Distribution of included CTs across medical fields
Fig. 4 Distribution of included CTs based on types of intervention
Bouça-Machado et al. BMC Palliative Care  (2017) 16:10 Page 5 of 12
possible to conclude which statistical analysis had been
used. Sample size calculation was not indicated in 38.3%
(n = 41) of studies, and 8.4% (n = 9) used a convenience
sample. Of the 57 studies that presented a sample size
calculation, in only 36.8% (n = 21) was the number of in-
cluded patients above the estimated sample size.
Dropouts
The mean sample size was 113.1 (SD 139.1) [range
9–820] participants, with a median of 64.5. The mean
dropout frequency (n = 99 studies) was 22%, 40.2% of
the studies had a dropout rate > 20% (cut-off used to
assess risk of bias). The main causes of attrition were symp-
tom burden and clinical deterioration. The clinical domains
and types of intervention with a higher percentage of stud-
ies with a dropout rate > 20% were: oncology (n = 30, 28%),
mental health (n = 11, 10.3%), pharmacological (n = 29,
27.1%), and non-pharmacological interventions (n = 23,
21.5%).
Pooled results from studies that reported one or more
dropouts (n = 91) showed higher dropout rates among
the active intervention groups (OR 1.32; 95% CI 1.07,
1.62). However, despite the use of a random effects
model, the high level of heterogeneity limits the accur-
acy of the meta-analysis results (Fig. 6).
Quality of reporting analysis
Only in two papers (1.9%) were all domains considered as
having low RoB, while in 33 (30.8%) there was a low RoB
in at least half of them (4/7 domains). In eight studies
(7.5%) there was a high RoB in at least half the cat-
egories and in 39 studies (36.5%) the risk of bias was
unclear (Additional file 3; Fig. 7).
The percentage of trials in the last 5 years that had a
low RoB in at least half the domains was higher compared
with trials published earlier (33.3% vs 29.7%). However,
the percentage of studies high or unclear RoB in at least
half the domains in the last 5 years was also higher (high
Rob – 9.1% vs 6.8%; unclear Rob – 42.4% vs 33.8%).
Only one study was not randomised. Computer-
generated randomisation was the most used mechanism,
present in 37.4% of studies (n = 40). Regarding the type
of randomisation: 23.4% (n = 25) used randomisation in
blocks, 15% (n = 16) stratified, 4.7% (n = 5) simple and
0.9% (n = 1) used a minimisation method. Most studies
used a person, unconnected with the study (e.g., an inde-
pendent statistical colleague or the pharmacist), to guar-
antee allocation concealment.
Regarding blinding (of participants, investigators and
outcome assessment), 19.6% (n = 21) of studies were
double-blind, 14% (n = 15) single-blind, in 6.5% (n = 7)
all elements were blinded and 19.6% (n = 21) were open-
label studies. In 40.2% (n = 43) this information was not
reported.
According to the instructions of the Cochrane tool,
when the primary outcome was not explicit, risk of bias
was considered to be high, since it was not clear if the
variables were chosen or not based on the results.
Discussion
This review identified 107 CCTs assessing PC interven-
tions for patients and/or families, the majority of them
performed in the USA and the UK. Only one study was
not randomized. The amount of missing data is very
high in almost all methodological factors evaluated.
Overall there is no data from the trial quality appraisal
to suggest that reporting of methods is improving.
Defining “palliative care”: who, what interventions, when?
In our review, we have chosen to accept as a palliative
intervention that which the authors assumed to be such.
As mentioned before, with increased awareness that
Fig. 5 Distribution of the most used evaluation scales in included studies
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non-oncology patients could benefit from a palliative ap-
proach, a series of transformations in the concept, inter-
ventions and objectives of “palliative care” occurred [1].
This diversity is reflected in the lack of a common lexi-
con in PC core terms (such as “palliative care” or “end-
of-life”) making it not only difficult to ensure that all
Fig. 6 Forest plot comparing dropouts between intervention and control group
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readers facing the same study reach similar conclusions,
but also to define the population and specific interven-
tions of palliative care [14, 26, 27]. Other reviews, such
as Lorenz et al. in 2005 review that intended to evaluate
the evidence in the field from the perspective of con-
cerns important to patients, caregivers, and the health
care system reported the same difficulties, and in 2003
Bausewein et al., in a review on the challenges defining
PC, highlighted the lack of clarity in definition and ter-
minology regarding this subject [28, 29].
Who?
Our results showed that there was a clear predominance
of interventions directed to oncological patients (e.g. the
comparison of two different methods of therapy adminis-
tration in the treatment of breakthrough pain in patients
with cancer) corresponding to 56.1% of the included stud-
ies. If at first this looks normal due to the initial focus of
PC on patients dying from cancer, the difference between
the percentage of oncology studies and studies of other
specialties (56.1% vs. 43.9%) seems to show that we are
now beginning to get used to the idea of PC in cancer, but
for other diseases this is far from reality. It is also relevant
that in 27.1% of the studies dementia was an exclusion cri-
terion. With people living longer and suffering more from
diseases that are associated with cognitive impairment, the
number of people who are demented and may benefit
from PC intervention is increasing. Therefore, cognitive
impairment and dementia should not be excluded from
the palliative care population, since this can threaten the
external validity of studies [30, 31].
What interventions?
Regarding the type of intervention, the number of studies
assessing pharmacological and non-pharmacological inter-
ventions was very similar (43.9% vs. 44.9%), with the ma-
jority of them evaluating interventions for symptomatic
control (70.1%). Other types of interventions, such as
non-pharmacologic complementary therapies (7.5%) and
home-care based (3.7%), or different aspects of care such
as communication (12.1%) or family support (5.6%) were
less covered. Albers et al. [26] and Hui et al. [32] in two
systematic reviews on methodological issues in PC,
pointed out the imbalance between pharmacological inter-
ventions and other interventions not related with symp-
tom control, which represented 5% or less of the total
RCTs in palliative care. The National Institute of Health
in the USA highlighted that few publications on palliative
care research reflected the growing needs of patients [33].
Even in the context of symptomatic control research, im-
portant gaps in clinical evidence should be addressed. For
example nonpain symptoms, such as breathlessness or de-
lirium, are still poorly understood and symptom burden
continues to be the main complaint of patients and cause
of dropout from studies despite relief of distressing symp-
toms being considered one of the guiding principles for
palliative care practitioners [10, 34].
When?
In this review the prognosis of patients ranged between
“less than one week” to 24 months. The definition of
palliative care points towards a population with life-
limiting disease and, when cure is not possible, what is
frequently understood as the care of patients in their last
weeks or days of life [10, 35]. However, some diseases,
especially chronic diseases, severely affect the quality of
life of patients and family members for many years, this
led to considering palliative care earlier, and including in
more recent definitions the initiation of palliative care at
the time of diagnosis and provided concordantly with all
other disease-directed or curative treatments [10].
The place of RCTs in palliative care research
Of the 939 identified citations, only 11.4% (n = 107) were
CCTs evaluating palliative care interventions in patients
and/or families. This is in line with previous methodo-
logical reviews, Hui et al. [5, 32] reported in 2011 that
RCTs only comprised 5.6% (n = 47) of the studies and in
Fig. 7 Risk of bias in included studies assessed using the Cochrane tool
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2006 Kaasa et al. [27], drew attention to the fact that
only 4.3% of publications were prospective evaluations
of interventions with case series (50.7%, n = 462) and
cross-sectional studies (17.7%, n = 149) being the most
common study designs. In 2014, Aoun and Nekolaichuk
[9] reported that Cochrane reviews in palliative care
failed to provide good evidence because of the few num-
bers and poor internal and external validity of primary
studies. Although these types of studies are a minority in
palliative care research, our results show that the num-
ber CCTs has increased in recent years.
Challenges performing RCTs in palliative care
Recruitment, attrition and powered samples
The samples of the included studies vary between 9 and
820 participants, with a median of 64.5. It is not uncom-
mon to find statements suggesting that it is unethical to
involve people with palliative care needs in research
because of their increased vulnerability [27]. Aoun and co-
workers [9], in a review about the challenges of evidence-
based medicine (EBM) in palliative care research demon-
strated precisely the opposite: the participation in experi-
mental protocols was not perceived as an additional
stress, but rather like a personal gain in a selfless perspec-
tive related with a moderate-to-high benefit. To care-
givers, this collaboration is seen as an added value for
patients, for themselves, and for future families that need
palliative care assistance. Recently, the result of a work-
shop and consensus exercise (MORECare study), about
best practice on ethical concerns in PC research [33],
affirmed that it is ethically desirable for patients and their
families with palliative care needs to be offered the oppor-
tunity to be involved in research and reminded of the
existence of relevant international recommendations to
overcome some of the ethical challenges faced. Abernethy
et al. [36], in a review on key insights to enhance the en-
rolment in palliative care trials, suggested strategies to
successfully recruit patients to large-scale randomised
clinical trials, for example where appropriate the adoption
of flexible interventions, the reduction of treatment time
periods, and the reduction of the number of study assess-
ments including in particular those that are invasive or
time consuming.
Our results show a median attrition rate of 22%. A re-
view by Hui et al. [13] found a median attrition rate of
44% in palliative oncological CT. When using a cut-off
of ≤ 20% of losses to follow-up and comparing with a re-
view of 71 RCT in four top medical journals showed a
dropout rates of ≥ 20% in 18% of the trials [25], we can
assume our 40.2% of studies above this cut-off as a high
dropout rate. It is unavoidable to have some missing data,
but ignoring it is not acceptable, since it represents a sig-
nificant risk to the power, precision and generalizability of
trials results. Looking at our pooled results, there was a
higher percentage of dropouts in intervention arm. Hus-
sain et al. [37] in a review on missing data in PC RCT re-
ported a similar result with a high dropout rate in
intervention arm. However, as we mentioned in results
section there was a high level of heterogeneity between
studies that didn’t allow to be conclusive in relation to this
question. Furthermore, Bell et al. [25] suggested that for
an accurate analysis of attrition bias in pooled results is
not enough to know the differential dropout rates, is also
necessary take into account the type of missingness (at
random, completely at random or not at random), the
analysis methods and the effect that is being estimated.
The authors suggested the use of mixed models methods
as a strategy to estimate unbiased treatment effects, under
assumptions regarding the misingness mechanism(s).
Of the 107 included clinical trials, only 53.3% of studies
reported a sample size calculation, and of these only 36.8%
(n = 21) reached the minimum of patients estimated. This
is a major problem in clinical research because, as men-
tioned above, it can be misleading either by missing realistic
moderate treatment effects that would be clinically import-
ant, or by overestimating the size of a treatment effect and
finding it statistically significant purely due to chance [38].
Visser et al. [5] already reported in 2015 that most of the
primary studies used in palliative care reviews were meth-
odologically flawed and those that were considered higher
quality were inadequately powered.
Outcomes and assessment tools
Besides the large diversity of study outcomes, our results
demonstrate the absence in a significant percentage of
studies (40.2%) of an explicit defined primary outcome,
which increases the risk of reporting bias since it is not
ensured that variables presented were not chosen based
on the study results. Because of the great heterogeneity
in population and type of interventions, there is still a
lack of consensus in palliative care field about the best
outcome measures and clinically meaningful differences
for each outcome.
In this review only 3.7% of the applied scales are in the
list recommended by The National Palliative Care Re-
search Center. The choice of assessment tools is very
important in study protocols and one of the challenges
of reaching high quality research. Although several in-
struments can be used to assess outcomes, not all were
developed and validated for use in a palliative care popu-
lation and so not the most appropriate [39].
The use of placebo-control trials
Our results show that the most used comparator was
non-intervention/best supportive care (46.7%, n = 50).
Best supportive care (BSC) interventions were defined
by Jassem et al. (2008) as “treatment administered with
the intent to maximize quality of life without a specific
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antineoplastic regimen” [40]. However, this method has
been criticised for poor reporting and for lack of stand-
ardisation among trial participants. To overcome these
threats, Nipp et al. [41] suggested the use of the pub-
lished BSC standards and the improvement in reporting
the components of BSC control arm [41, 42].
The placebo effect has been shown to be relatively
consistent over many studies and has been approximated
to account, in general, for up to 35% of the treatment ef-
fect [43]. In 1997 two articles [44, 45] with arguments
for and against placebo-controlled trials in palliative care
were published. The two agree that many of the inter-
ventions in palliative care have never been proven to be
effective and their use is based on anecdotal reports
and/or physician preferences. Hardy et al. (1997), in line
with the tenets of evidence-based medicine [43], used
this as one of the reasons to encourage the use of
placebo-controlled trials and states that when there is no
evidence that a drug is better than placebo, and knowing
the powerful effect of placebo, there can be no argument
against its use [44].
Quality of reporting analysis
A key finding of this systematic review was the low over-
all reporting quality of CTs in palliative care and the
amount of missing data in trial reporting. Although the
number of published studies has increased significantly
in the last years, we found no relevant improvement in
the overall methodological quality of studies. Only 2/107
papers (1.9%) were evaluated as having a low risk of bias
in all domains, and 30.8% (n = 33) in at least half of do-
mains. A review of evidence-based practice in palliative
care from 2015 [5] supports our findings and attributes
the poor quality of trials to the barriers that were already
mentioned in this review, such as difficulties in recruit-
ment, in reaching samples with a significant power, and
in defining outcomes. In another study from 2014 the
authors state that recent reviews in the field continue to
report a lack of strong evidence for important topics,
due in part to the methodological weaknesses in the
existing studies [46].
Allocation concealment and blinding were the aspects
poorly reported. Lai [47], in a systematic review of pri-
mary treatment in brain tumours, suggested that alloca-
tion concealment, blinding, type of analyses and details
of randomisation were the poorly reported aspects be-
cause of the researcher difficulty in reporting this type
data and due to the lack of awareness of the importance
of these features. Regarding blinding, in many interven-
tions this method is difficult to apply. However, it is
important to use it to minimise bias, especially when the
outcome of interest is subjective [48]. The “other bias” do-
main has the highest percentage of “uncertain risk of bias”.
The assessment of this item was based on comparability of
trial arms and sample size calculations, but most of all with
a global evaluation of methodological flaws and amount of
missing information in each trial (Additional file 4). Studies
with major gaps in other key methodological characteristics
commonly also did not fulfil our criteria for a low risk of
other bias.
Quality of a clinical trial is a multidimensional concept
that includes study design, conduction, type of analysis,
clinical relevance and quality of reporting [49]. In this
review we evaluated the quality of reporting, and based
on this indirectly inferred studies quality. The focus on
the assessment of trial reporting is based on the evi-
dence that studies of lower methodological quality tend
to report larger treatment effects than high quality stud-
ies [50–52]. It cannot be excluded that obtaining add-
itional information from study protocols or directly from
trial investigator could ensure a more accurate assess-
ment of studies quality [9, 53].
Chen et al. [46], in a survey of palliative care researchers
about the barriers to improving research in palliative care,
highlights as one of the five major identified barriers the
lack of research training programs and formal training op-
portunities, such as research fellowships, which are limit-
ing factors in equipping a researcher workforce. Today,
to assist investigators in this field, tools such as the
CONSORT statement and SPIRIT, were created to help
in the reporting of study results and to raise the quality
of studies [18, 54].
Shortcomings
Although the current study had included a pre-specified
search strategy and two independent investigators per-
formed the selection, we were restricted to one database
(MEDLINE), which can not ensure we have identified all
studies that meet the eligibility criteria. As mentioned
above, there is a large variability in palliative care termin-
ology. For that reason the identification of clinical trials in
this review was made, not according to a specific and
strict definition, but in line with author’s assumption of
what constitutes a palliative care intervention. As a result,
the number of retrieved citations was high, with an ele-
vated percentage of manuscripts that did not meet inclu-
sion criteria for clinical trials. Of the 939 identified
citations, 107 met the inclusion criteria and were analysed.
Compared with previous reviews, our search strategy gen-
erated the largest list of clinical trials concerning thera-
peutic interventions in palliative care appraised and we
believe that our results are representative of interventional
studies in PC.
Conclusions
With palliative care research becoming increasingly ne-
cessary it is not enough to conduct more studies, it is
also necessary to improve the quality of evidence.
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Palliative care research is trying to deal with the large
heterogeneity, the ethical and methodological issues
resulting from the expansion of its scope of intervention,
while at the same time it still seems too tied to the con-
cept of terminal care of oncological patients, with a level
of quality of reporting that has not evolved.
To our knowledge, this is the most comprehensive at-
tempt to review clinical trials in palliative care literature.
According to our results, it seems that the first step in
generating not just valid, but also generalisable knowledge,
is to clearly define palliative care populations, types of
intervention and time to referral, establishing a common
lexicon for clinicians and researchers. This will allow con-
sensus to be achieved on the best outcomes and clinically
meaningful differences, and will facilitate the choice of
study design as well as promoting strategies to bypass the
major barriers in palliative care research. The use of tools
to help reporting study outcomes, such as CONSORT or
SPIRIT, could also be a simple and efficient way of im-
proving the quality of studies.
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